Seagen Inc.
https://www.seagen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Seagen Inc.
Seagen, Genmab See Broad Cervical Cancer Opportunity For Tisotumab Vedotin
At ESMO, data showed overall response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.
Enhertu Poised To Rewrite The Standard Of Care After ESMO
AstraZeneca/Daiichi Sankyo's Enhertu is poised to become the new standard of care for second-line HER2-positive breast cancer after handedly beating Roche's Kadcyla on PFS.
BeiGene’s Brukinsa Among Nine Drugs To Win EU Marketing Thumbs Up
A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval.
Gilead Builds Up Trodelvy Data In TNBC Ahead Of Competition
Phase III sub-analyses presented at ESMO show the drug providing a survival benefit in a complex subpopulation, as well as improvements to quality of life.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Alpine Biosciences
- Biomira
- Oncothyreon, Inc.
- Cascadian Therapeutics, Inc.
- Seattle Genetics, Inc.